Evidence map›Paper›PMID 34484423›Full record

ReviewTherapeutic advances in gastroenterology2021

Autoimmune gastritis, with or without pernicious anemia: epidemiology, risk factors, and clinical management.

Sheila D Rustgi, Priyesha Bijlani, Shailja C Shah

Registry-linked trialOpen access · goldAbstract readReview
In one paragraph

Review in Therapeutic advances in gastroenterology, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT06272500 (Safety and Efficacy Study of Betaine Hydrochloride in Treating Hypergastrinemia in Patients With Autoimmune Gastritis.), which is not on this map. Cited by 42 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
42citing papers in PubMed, 1 pooled it
13.6field-weighted citation impact, top 1% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT06272500 narecruitingnot on this mapstarted 2024, after this paper: background citation

Safety and Efficacy Study of Betaine Hydrochloride in Treating Hypergastrinemia in Patients With Autoimmune Gastritis.

TypeinterventionalSponsorJianning YaoRan2024 to 2026Enrolled60ConditionsAutoimmune GastritisArmsoral administration of receives only oral administration of placebo, oral administration of Betaine hydrochloride
3 · Its place in the literature

Who cites it

42 citing papers in PubMed, 1 synthesis or guideline pooled it, 102 citations in OpenAlex.

  1. Pooled it
  2. Article
  3. Article
  4. Article
  5. Article
  6. Article
  7. Article
  8. Article
  9. Gyrus-like endoscopic changes in autoimmune gastritis with pastWorld journal of gastrointestinal endoscopy · 2025
    Article
  10. Article
  11. Article
  12. Review
  13. Review
  14. Gastric cancer in patients withWorld journal of gastrointestinal oncology · 2025
    Article
  15. Review
  16. Article
  17. Article
  18. Article
  19. Review
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

3 authors at 2 institutions in 1 country.

Sheila D RustgiVagelos College of Physicians and Surgeons, Columbia University, New York, NY, USA; Division of Digestive and Liver Diseases, Columbia University Irving Medical Center, New York, NY, USA.ORCID https://orcid.org/0000-0002-1889-1652
Priyesha BijlaniDepartment of Medicine, University of California, San Diego, La Jolla, CA, USA.
Shailja C ShahSection of Gastroenterology, VA San Diego Healthcare System, 3350 La Jolla Villa Drive, San Diego, CA 92161, USA.ORCID https://orcid.org/0000-0002-2049-9959
University of California San Diego · USColumbia University · US

Funding

Learning Health System Scholar Program at VanderbiltK12HS026395 · AHRQ · VANDERBILT UNIVERSITY MEDICAL CENTER · PI ROTHMAN, RUSSELL L., ROUMIE, CHRISTIANNE L. · 2018 to 2022
$2.7M
AHRQ HHS K12 HS026395CSRD VA IK2 CX002027
6 · The paper itself

Abstract

Autoimmune gastritis (AIG) is a chronic immune-mediated, inflammatory condition that involves the destruction of the gastric oxyntic mucosa through the autoimmune-mediated loss of parietal cells, with replacement by atrophic and metaplastic tissue. Diagnosing AIG is important, given the need for ongoing clinical management and vigilance with respect to downstream complications, the most serious of which is gastric adenocarcinoma. Other clinical consequences include gastric neuroendocrine tumors, consequences related to decreased gastric acid and decreased intrinsic factor due to parietal cell destruction and antibodies against intrinsic factor (e.g. micronutrient deficiencies), as well as concomitant autoimmune disorders. Considering the prevalence of AIG and the potential for severe clinical outcomes, it is important to engage in efforts to reduce practice pattern variability related to diagnosis and management. Accordingly, herein, we review of the epidemiology, pathogenesis, clinical presentation of AIG, including both gastric and extragastric manifestations, and provide an overview of clinical management.

Indexed as

atrophic gastritiscarcinoidgastric neoplasmHelicobacter pyloriintestinal metaplasiairon deficiencyneuroendocrine tumorsvitamin B12 deficiency

Identifiers

PMID34484423
PMCPMC8414617
OpenAlexW3198064372

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.